On the heels of warnings from the U.S. Food and Drug Administration about the risks of using power morcellators in uterine surgery, the Judicial Panel on Multidistrict Litigation has been asked to consolidate 21 federal suits against makers of the devices—and lawyers involved in the litigation predict that while the number of cases will not be large, their value could be significant.
Plaintiffs in power morcellator cases tend to have major medical bills and most are within the peak earning years of 40 to 60, according to those lawyers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
